Navigation Links
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
Date:4/14/2008

Isis Will Host a Conference Call on Monday, April 14, at 8:30 a.m. E.T. at

http://www.isispharm.com

CARLSBAD, Calif., April 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced additional results from its ongoing Phase 2 open-label extension (OLE) study of mipomersen in patients with familial hypercholesterolemia (FH). In FH patients exposed to mipomersen for as long as 16 months, the safety profile of the drug continues to be encouraging. Reductions in LDL-cholesterol were also maintained in patients who had responded to treatment in their initial study and continued on treatment.

In this OLE study, patients with FH who were initially enrolled in one of two Phase 2 efficacy studies of mipomersen were allowed to enter the OLE study. All patients in the study were being treated with maximum-tolerated lipid-lowering therapy before and during the study. Most patients received 200 mg/week of mipomersen in addition to maximum-tolerated lipid-lowering therapy. The median duration of continuous exposure in these patients was 38 weeks. The maximum continuous exposure was 64 weeks.

All patients in the study had the opportunity to self-administer mipomersen. Although the study was not designed to measure efficacy, the activity of mipomersen was clearly demonstrated and appeared to be well maintained with longer-term dosing.

With respect to safety, the drug was well tolerated in longer-term treatment. There were no new types of adverse events observed and rates of adverse events decreased during the OLE study from those in the initial efficacy studies.
The following additional observations were made in thes
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
6. Anti-Cancer Drug CYT997 Update
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting ... the quarter ended June 30, 2015 and provided ... "The second quarter of 2015 and recent ... Regulus," said Paul Grint, M.D., President and CEO ...
(Date:8/4/2015)... , Aug. 04, 2015 ... has announced the addition of the "MRI ... Comfort and Operational Efficiency, with Growth Driven by ... "MRI Systems Market to 2020 - Focus ... Driven by Developing Economies" discusses the market, competitive ...
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
Breaking Medicine Technology:Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2
... LAUSANNE, Switzerland, October 5 ... of companies with,a focus on the development of ... Japanese Cancer Association (JCA) presented ,The JCA-Mauvernay,Award, to ... Research,Institute in Tokyo, for his outstanding and innovative ...
... Oct. 2 The next major personalized medicine advances will ... change in the health care industry to gain access, the ... Ohio State University Medical Center,s Personalized Health Care ... of the Institute for Systems Biology, said personalized medicine,s first ...
Cached Medicine Technology:The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research 2The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research 3Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:8/4/2015)... Mountain View, CA (PRWEB) , ... August 04, ... ... 17th Surgeon General of the United States, Richard Carmona, M.D., M.P.H., FACS, to ... prevents catastrophic medication errors and will save lives," Dr. Carmona said. "I strongly ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the safety ... is standing up as a voice of authority for men seeking accurate information about ... with special experience and expertise in the safe and effective treatment of low testosterone. ...
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a thousand ... and medical art can be essential. StayWell, a health solutions company, announced today it ... solutions have been used by physicians and other health care providers for more than ...
(Date:8/4/2015)... Calif. (PRWEB) , ... August 04, 2015 , ... ... corporations, law firms and government entities, today announced that John Munro, a 15-year ... as Vice President of Managed Services Operations. , “I am thrilled to join ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... engineering David Bruce will participate in a multi-university Energy ... the U.S. Department of Energy. The Center for Atomic-Level ... new catalysts for the production of clean fuels and ... of CALCD, combined with those of 45 other new ...
... Calif., July 7 XTENT, Inc. (Nasdaq: XTNT ) ... which was scheduled to take place at 9:00 a.m. Pacific Time ... for 9:00 a.m. Pacific Time on August 3, 2009. ... its board of directors had unanimously approved a Plan of Complete ...
... Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI ), the leader ... offered a corporate update by its chief executive officer, Rick ... quarter for ZixCorp and we are on target to report ... "Preliminary estimates are that we should meet our revenue guidance ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that ... a public offering. Piper Jaffray & Co. will be the ... pursuant to a shelf registration statement filed with the Securities ... on December 3, 2008. A prospectus supplement relating to the ...
... , NEW YORK, July 7 As part of ... Jersey healthy, MagnaCare, the region,s recognized leader in innovative ... announce the launch of its new full-service pharmacy benefit ... are demanding better solutions for pharmacy benefit management. With ...
... Reduced-dose schedule for PCV-7 vaccine supported by study findings ... babies alike will be relieved by new findings that ... protect infants against pneumonia and other infections. , The ... (PCV-7) consists of three primary doses before the age ...
Cached Medicine News:Health News:DOE funds Clemson University clean energy research 2Health News:XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 3Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 4Health News:MagnaCare Answers Need for New Prescription Drug Program 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2
Adson bipolar forceps, 12 cm, straight....
Bipolar foot activated forceps....
Olsen bayonet forceps, designed by Mr. Olsen in a configuration with 3 holes to make them lighter, more flexible, and also to ensure maximum grip for different procedures where there is limited acces...
Bayonet fine, smooth - 1/box....
Medicine Products: